XML 62 R43.htm IDEA: XBRL DOCUMENT
v3.23.3

Commitments and Contingencies (Details Narrative) |  |  |  |  |  |  |  |  |  |  |  | 2 Months Ended | 3 Months Ended | 8 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 05, 2023 USD ($) | Sep. 26, 2023 USD ($) | Jun. 22, 2023 USD ($) | Apr. 17, 2023 USD ($) | Nov. 06, 2022 USD ($) | Jun. 10, 2022 USD ($) | Apr. 09, 2021 USD ($) | Feb. 05, 2021 USD ($) | Aug. 20, 2018 USD ($) | Sep. 14, 2015 USD ($) | Dec. 24, 2013 USD ($) | Aug. 31, 2020 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Oct. 03, 2023 USD ($) | Oct. 03, 2023 EUR (€) | Oct. 08, 2021 EUR (€)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual commitment |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,262,000 |  | $ 6,262,000 | $ 6,262,000 |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | 132,487 | $ 272,388 |  | 749,029 | $ 895,649 |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  | 84,000 |  | 84,000 | 84,000 |  |  |  |
Forman [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Compensation |  |  |  |  | $ 200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Paid office rent |  |  |  |  | $ 1,500 |  |  |  |  |  |  |  | 7,323 |  |  | 11,436 |  |  |  |
Officer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Compensation |  | $ 950,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Officer [Member] | Minimum [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Compensation | $ 700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  | 74,181 |  | 74,181 | 74,181 |  |  |  |
Moffitt Cancer Center and Research Institute Hospital Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 148,138 |  |  |  |
GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 684,652 |  |  |
NDA Consulting Corp [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory fee |  |  |  |  |  |  |  |  |  |  | $ 4,000 |  | 4,000 | 4,000 |  | 12,000 | 12,000 |  |  |
Clinical Trial Research Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development process costs |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 9,218 |  | 0 | 18,623 |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 131,074 |  |  |  |  |
Other Clinical Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,144,000 |  |  |  |
Collaboration Agreement [Member] | GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 268,829 | 0 |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  | 3,423,000 |  | 3,423,000 | 3,423,000 |  |  |  |
Collaboration Agreement [Member] | Bio Pharma Works LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory fee |  |  |  |  |  |  |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |
Reimbursed expense |  |  |  |  |  |  |  |  |  |  |  |  | 30,000 | 30,000 |  | 90,000 | 90,000 |  |  |
Clinical Research Support Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  | 800,000 |  | 800,000 | 800,000 |  |  |  |
Clinical Research Support Agreement [Member] | City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 69,001 | 0 |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  | 2,433,000 |  | 2,433,000 | 2,433,000 |  |  |  |
Total costs |  |  |  |  |  |  |  |  |  |  |  |  | 447,512 |  | 447,512 | 447,512 |  |  |  |
Work Order Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  | 144,000 |  | 144,000 | 144,000 |  |  |  |
Total costs |  |  |  |  |  |  |  |  |  |  |  |  | 10,000 |  | 10,000 | 10,000 |  |  |  |
Work Order Agreement [Member] | City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  | $ 335,000 |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  | 262,000 |  | 262,000 | 262,000 |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 4,500 | 7,731 |  | 15,740 | 23,466 |  |  |
Work Order Agreement [Member] | Theradex Systems, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | 3,750 |  |  | 10,000 |  |  |  |
Work cost |  |  | $ 153,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payment through services |  |  | 72.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of payment through software |  |  | 28.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Work Order Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | 566 | 11,953 |  | 20,850 | 19,792 |  |  |
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non refundable license issue fee |  |  |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |
Maintenance fee |  |  |  |  |  |  |  |  | 25,000 |  |  |  |  |  |  |  |  |  |  |
Payment on non refundable milestone |  |  |  |  |  |  |  |  | $ 1,897,000 |  |  |  |  |  |  |  |  |  |  |
Operating costs and expenses |  |  |  |  |  |  |  |  |  |  |  |  | 21,507 | 6,301 |  | 9,109 | 18,699 |  |  |
Employment Agreement [Member] | Executive Officers [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Salary and compensation |  |  |  |  |  |  |  |  |  |  |  | $ 640,000 |  |  |  |  |  |  |  |
Employment Agreement [Member] | Dr.James [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual compensation |  |  |  |  |  |  | $ 775,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Employment Agreement [Member] | Bastiaan van der Baan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual salary |  | $ 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 416,356 |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  | 316,000 |  | $ 316,000 | 316,000 |  |  |  | € 391,000
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 51,568 | 46,068 |  | 156,949 | 149,184 |  |  |
Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 263,000 | € 250,000 |
MRI Global [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 241,841 |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 19,845 | $ 5,549 |  | $ 27,028 | $ 25,902 |  |  |
Contract price |  |  |  | $ 326,274 |  | $ 273,980 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Advance amount related to milestone payment. + References No definition available. + Details
Name: | LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount related to milestone payment. + References No definition available. + Details
Name: | LIXT_AmountRelatedToMilestonePayment
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Company is obligated to pay annual license maintenance fee. + References No definition available. + Details
Name: | LIXT_AnnualLicenseMaintenanceFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consulting and advisory quarterly cash fee. + References No definition available. + Details
Name: | LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contract price. + References No definition available. + Details
Name: | LIXT_ContractPrice
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Estimated work cost. + References No definition available. + Details
Name: | LIXT_EstimatedWorkCost
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of expected paymen through software. + References No definition available. + Details
Name: | LIXT_ExpectedPaymentThroughSoftware
Namespace Prefix: | LIXT_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected payment in services. + References No definition available. + Details
Name: | LIXT_ExpectedPaymentinServices
Namespace Prefix: | LIXT_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Company is obligated to pay non refundable license issue fee.. + References No definition available. + Details
Name: | LIXT_NonRefundableLicenseIssueFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones. + References No definition available. + Details
Name: | LIXT_PaymentsOnNonrefundableMilestone
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reimbursement expense. + References No definition available. + Details
Name: | LIXT_ReimbursementExpense
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details
Name: | us-gaap_DeferredCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of expense for employee benefit and equity-based compensation. + References No definition available. + Details
Name: | us-gaap_EmployeeBenefitsAndShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_OfficersCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + References No definition available. + Details
Name: | us-gaap_OperatingCostsAndExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash payments to lessor's for use of assets under operating leases. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForRent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_SalariesAndWages
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + References No definition available. + Details
Name: | us-gaap_SalariesWagesAndOfficersCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_TitleOfIndividualAxis=LIXT_FormanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=srt_OfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalResearchSupportAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=LIXT_ExecutiveOfficersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=LIXT_BastiaanVanDerBaanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_DevelopmentCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_NetherlandsCancerInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_MRIGlobalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |